Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma

Pediatric Blood and Cancer

Volumn 61, Issue 2, 2014, Pages 383-386

  Bourdeaut, Franck ^a,b   Miquel, Catherine ^c,d   Richer, Wilfrid ^a   Grill, Jacques ^e   Zerah, Michel ^d,f   Grison, Camille ^b   Pierron, Gaelle ^b   Amiel, Jeanne ^d,f   Krucker, Clementine ^b   Radvanyi, Francois ^b   Brugieres, Laurence ^e   Delattre, Olivier ^a,b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c CENTRE HOSPITALIER SAINTE ANNE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

CREBBP; Medulloblastoma; Predisposition; Rubinstein Taybi syndrome

Indexed keywords

BETA CATENIN; CREBBP PROTEIN; FILAMIN A; MYC PROTEIN; SONIC HEDGEHOG PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CANCER SUSCEPTIBILITY; CASE REPORT; CHROMOSOME 16; GENE EXPRESSION; HUMAN; IMMUNOREACTIVITY; INFANT; MALE; MEDULLOBLASTOMA; PRIORITY JOURNAL; RUBINSTEIN SYNDROME;

EID: 84890887934     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24765     Document Type: Article

References (21)

1. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29:1408-1414.
2. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012; 123:473-484.
3. Robinson G, Parker M, Kranenburg TA, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488:43-48.
4. Jones DT, Jäger N, Kool M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488:100-105.
5. Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012; 488:106-110.
6. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995; 332:839-847.
7. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002; 31:306-310.
8. Brugières L, Remenieras A, Pierron G, et al. High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. J Clin Oncol 2012; 30:2087-2093.
9. Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012; 148:59-71.
10. Bourdeaut F, Miquel C, Di Rocco F, et al. FGF receptors germline mutations and medulloblastomas. Am J Med Genet 2013; 161A:382-385.
11. Fattet S, Haberler C, Legoix P, et al. Beta-catenin status in paediatric medulloblastomas: Correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 2009; 218:86-94.
12. Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: Clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 2011; 121:381-396.
13. Gervasini C, Castronovo P, Bentivegna A, et al. High frequency of mosaic CREBBP deletions in Rubinstein-Taybi syndrome patients and mapping of somatic and germ-line breakpoints. Genomics 2007; 90:567-573.
14. Miller RW, Rubinstein JH. Tumors in Rubinstein-Taybi syndrome. Am J Med Genet 1995; 56:112-115.
15. Evans G, Burnell L, Campbell R, et al. Congenital anomalies and genetic syndromes in 173 cases of medulloblastoma. Med Pediatr Oncol 1993; 21:433-434.
16. Skousen GJ, Wardinsky T, Chenaille P. Medulloblastoma in patient with Rubinstein-Taybi syndrome. Am J Med Genet 1996; 66:367.
17. Taylor MD, Mainprize TG, Rutka JT, et al. Medulloblastoma in a child with Rubenstein-Taybi syndrome: Case report and review of the literature. Pediatr Neurosurg 2001; 35:235-238.
18. Knudson AG. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68:820-823.
19. Wu X, Northcott PA, Dubuc A, et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 2012; 482:529-533.
20. Pfaff E, Remke M, Sturm D, et al. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 2010; 28:5188-5196.
21. Lindsey JC, Hill RM, Megahed H, et al. TP53 mutations in favorable-risk Wnt/Wingless-subtype medulloblastomas. J Clin Oncol 2011; 29:344-346.